RxDoctor Payments Data

Araj Sidki, DO

Interventional Pain Medicine · Plainview, NYNPI 1285014126

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,914 of the $4,638 with a category attached, or 62.8%. 17 manufacturers reported payments, led by Boston Scientific at 31.3% of the total. 2025 is the largest year on record at $1,706, 7.0 times the $244 reported in 2020.

$4,638in general payments, 2019–2025

Across 81 payments — averaging $57.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Saluda Medical Americas, Inc.$1K
  • Scilex Pharmaceuticals Inc.$458
  • AbbVie$325
  • Abbott$271
  • Medtronic$253
  • plus $691 from 11 others

What the payments were for

  • Travel & lodging$1,70937%
  • Food & beverage$2,91463%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,638 in reported general payments places this provider in the 55th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$339,527
Medicare patients
350
Services billed
3,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin122$894
Lidocaine15$721
Oxycodone Hcl84$680
Tramadol Hcl90$618
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen66$523
Naproxen56$300
Pregabalin13$295
Cyclobenzaprine Hcl49$287
Methylprednisolone16$174
Meloxicam47$141
Tizanidine Hcl17$105
Diazepam32$48

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →